Executive Vice President, International Operations
Raymond Francot joined the company in January 2018. He previously served as Myriad’s Chief Commercial Officer in Europe. Prior to joining Myriad, Mr. Francot was Vice President and Regional General Manager for Vertex Pharmaceuticals GmbH. Prior to Vertex, he was General Manager at Gilead Sciences Germany GmbH, where he developed the company’s HIV franchise in Germany, Austria and Switzerland. Mr. Francot’s first role in the life sciences industry was with Baxter Healthcare where he held various international commercial positions within the renal division. Mr. Francot received his undergraduate and master’s degrees in law studies from the University of Maastricht and a master’s in business administration from Erasmus University of Rotterdam.
Country Manager, Japan
Gary A. King joined the company in July 2010 and has been employed in the life sciences industry for more than 35 years. Prior to Myriad, he was the Chief Executive Officer of AverDx Incorporated, an international biotechnology company. Before AverDx, he was Vice President, International Operations at Biosite Incorporated where he spent six years building and leading all of the Company’s commercial activities outside the United States. Prior to joining Biosite, Mr. King was Division Director in Japan for Guidant Corporation and led Guidant’s transition from distributor to direct operations in the Japanese market. Mr. King received his Bachelor of Arts degree in Zoology from Pomona College and a Masters of Business Administration degree from Stanford University.
Director, International Medical Affairs
Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director International Medical Affairs. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg.
In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett co-founded Sividon Diagnostics GmbH and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.
Director Customer and Kits Operations
Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.
Vice President of FP&A
Nathan A. Smith, controller, joined Myriad in January 2008. As the controller, Mr. Smith has been engaged in various corporate transactions including the spin-off of Myriad’s former drug development business as well as various business and asset acquisitions. In addition, Mr. Smith oversees the corporate financial statement close process in Oracle and Hyperion including the accounting review of revenue, liabilities, royalties, contractual agreements, share-based compensation arrangements and the income tax provision. He also leads the compilation and reporting of the quarterly and annual financial results as well as various other filing and submissions to the Securities and Exchange Commission.
Mr. Smith began his career with Ernst & Young in their Assurance & Advisory Business Services in May 2002 where he held several positions. During his tenure there, he worked with a variety of public companies and start-up companies. Mr. Smith helped advise clients on initial public offerings, financial statement reporting and internal control related issues, mergers and acquisitions, Sarbanes-Oxley compliance, SEC reporting, and various accounting and auditing related matters
Mr. Smith received a Bachelor of Science degree from Brigham Young University and a Master of Accounting degree from the University of Virginia and is a Certified Public Accountant licensed in the states of Utah and Colorado.